SG11201908517XA - Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders - Google Patents
Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disordersInfo
- Publication number
- SG11201908517XA SG11201908517XA SG11201908517XA SG11201908517XA SG 11201908517X A SG11201908517X A SG 11201908517XA SG 11201908517X A SG11201908517X A SG 11201908517XA SG 11201908517X A SG11201908517X A SG 11201908517XA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- san francisco
- south san
- international
- dna way
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017077059 | 2017-03-17 | ||
| PCT/CN2018/079292 WO2018166528A1 (en) | 2017-03-17 | 2018-03-16 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908517XA true SG11201908517XA (en) | 2019-10-30 |
Family
ID=63522807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908517X SG11201908517XA (en) | 2017-03-17 | 2018-03-16 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10968203B2 (zh) |
| EP (1) | EP3596063A4 (zh) |
| JP (1) | JP6925435B2 (zh) |
| KR (1) | KR20190141145A (zh) |
| CN (1) | CN111247136A (zh) |
| AR (1) | AR111281A1 (zh) |
| AU (1) | AU2018233402A1 (zh) |
| BR (1) | BR112019019193A2 (zh) |
| CA (1) | CA3056833A1 (zh) |
| CL (1) | CL2019002671A1 (zh) |
| CO (1) | CO2019010078A2 (zh) |
| CR (1) | CR20190433A (zh) |
| IL (1) | IL269302A (zh) |
| PE (1) | PE20191557A1 (zh) |
| SG (1) | SG11201908517XA (zh) |
| TW (1) | TW201838981A (zh) |
| WO (1) | WO2018166528A1 (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7126084B2 (ja) | 2017-06-01 | 2022-08-26 | コーネル ユニバーシティー | Ｉｒｅ１小分子阻害薬 |
| US10392367B2 (en) | 2017-06-01 | 2019-08-27 | Quentis Therapeutics, Inc. | IRE1 small molecule inhibitors |
| US20210198238A1 (en) * | 2018-08-30 | 2021-07-01 | The Regents Of The University Of California | Ire1 kinase inhibitors and uses thereof |
| JP7098826B2 (ja) * | 2018-09-12 | 2022-07-11 | ジェネンテック， インコーポレイテッド | ピリミジニル－ヘテロアリールオキシ－ナフチル化合物および使用方法 |
| SG11202105690TA (en) * | 2018-12-03 | 2021-06-29 | Univ Cornell | Ire1 small molecule inhibitors |
| US11945784B2 (en) | 2018-12-03 | 2024-04-02 | Cornell University | IRE1 small molecule inhibitors |
| WO2020232403A1 (en) * | 2019-05-15 | 2020-11-19 | Cornell University | Treatment of fibrosis with ire1 small molecule inhibitors |
| WO2022032078A1 (en) * | 2020-08-07 | 2022-02-10 | Optikira, LLC | Pyrazolopyridine compounds and methods of inhibiting ire1 using same |
| WO2022104151A1 (en) * | 2020-11-13 | 2022-05-19 | The Regents Of The University Of California | Ire1alpha inhibitors and uses thereof |
| CN116710429A (zh) * | 2020-11-13 | 2023-09-05 | 加利福尼亚大学董事会 | IRE1α抑制剂及其用途 |
| CN114907350B (zh) * | 2021-02-10 | 2023-12-29 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物、制备方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5097539B2 (ja) * | 2004-05-07 | 2012-12-12 | アムジエン・インコーポレーテツド | タンパク質キナーゼ調節剤および使用方法 |
| US7868177B2 (en) | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| CA2737388C (en) | 2008-09-15 | 2017-07-11 | Peter Walter | Methods and compositions for modulating ire1, src, and abl activity |
| ES2638317T3 (es) | 2013-04-04 | 2017-10-19 | Janssen Pharmaceutica Nv | Nuevos derivados de N-(2,3-dihidro-1H-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina y N-(2,3-dihidro-1H-indol-5-il)-4-quinazolinamina como inhibidores de PERK |
-
2018
- 2018-03-15 AR ARP180100604A patent/AR111281A1/es unknown
- 2018-03-15 TW TW107108924A patent/TW201838981A/zh unknown
- 2018-03-16 CR CR20190433A patent/CR20190433A/es unknown
- 2018-03-16 PE PE2019001893A patent/PE20191557A1/es unknown
- 2018-03-16 WO PCT/CN2018/079292 patent/WO2018166528A1/en active Application Filing
- 2018-03-16 CA CA3056833A patent/CA3056833A1/en not_active Abandoned
- 2018-03-16 EP EP18768363.6A patent/EP3596063A4/en active Pending
- 2018-03-16 KR KR1020197030386A patent/KR20190141145A/ko not_active Application Discontinuation
- 2018-03-16 JP JP2019551376A patent/JP6925435B2/ja active Active
- 2018-03-16 CN CN201880032314.6A patent/CN111247136A/zh active Pending
- 2018-03-16 SG SG11201908517X patent/SG11201908517XA/en unknown
- 2018-03-16 BR BR112019019193A patent/BR112019019193A2/pt not_active Application Discontinuation
- 2018-03-16 AU AU2018233402A patent/AU2018233402A1/en not_active Abandoned
- 2018-05-24 US US15/989,008 patent/US10968203B2/en active Active
-
2019
- 2019-09-12 IL IL26930219A patent/IL269302A/en unknown
- 2019-09-17 CL CL2019002671A patent/CL2019002671A1/es unknown
- 2019-09-18 CO CONC2019/0010078A patent/CO2019010078A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6925435B2 (ja) | 2021-08-25 |
| JP2020514377A (ja) | 2020-05-21 |
| IL269302A (en) | 2019-11-28 |
| US20180265497A1 (en) | 2018-09-20 |
| CO2019010078A2 (es) | 2020-01-17 |
| KR20190141145A (ko) | 2019-12-23 |
| EP3596063A1 (en) | 2020-01-22 |
| CL2019002671A1 (es) | 2019-12-06 |
| BR112019019193A2 (pt) | 2020-04-22 |
| CN111247136A (zh) | 2020-06-05 |
| WO2018166528A1 (en) | 2018-09-20 |
| TW201838981A (zh) | 2018-11-01 |
| AU2018233402A1 (en) | 2019-10-10 |
| EP3596063A4 (en) | 2020-12-30 |
| AR111281A1 (es) | 2019-06-26 |
| CR20190433A (es) | 2019-11-20 |
| CA3056833A1 (en) | 2018-09-20 |
| US10968203B2 (en) | 2021-04-06 |
| PE20191557A1 (es) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201807708SA (en) | Estrogen receptor modulators | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same |